Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

Candriam Equities L Biotechnology C Cap

Ranked 2 out of 4 in - Biotechnology over 12 months
All calculations are in EUR unless stated

Objective

The fund invests in biotechnology companies and in related activities (e.g. molecular diagnostics & scientific equipment). It has a worldwide scope but given the innovative history of the US biotechnology sector, most of the assets are invested in the US.

Showing fund performance in Belgium View performance globally

Performance

Biotechnology over : 31/10/2016 - 31/10/2017

Total Return

Quarterly Performance

to 29/09/2017 Annual Q1 Q2 Q3 Q4
2017 11.3% 0.6% 6.5%
2016 -17.1% -27.6% 2.9% 12.9% -1.4%
2015 20.5% 25.3% 1.9% -18.0% 14.9%
2014 54.3% 4.6% 8.1% 15.2% 18.5%
2013 57.4% 22.9% 5.3% 17.7% 3.4%
2012 29.3% 15.7% 8.9% 8.2% -5.2%
2011 6.0% 0.2% 3.5% -10.6% 14.3%
2010 32.3% 33.8% -10.7% 2.4% 8.1%
2009 39.9% 1.9% 3.8% 28.9% 2.7%
2008 -15.8% -14.1% 0.9% 17.4% -17.3%
2007 -10.4% -0.3% -0.2% -0.8% -9.2%
2006 -2.7% 3.7% -13.8% 1.1% 7.6%
2005 34.8% -8.4% 21.0% 15.1% 5.7%
2004 -0.5% 10.3% -2.2% -3.7% -4.3%
2003 19.8% -3.4% 18.5% 5.7% -1.0%
2002 -53.7% -15.3% -40.8% -6.9% -0.8%
2001 -11.5% -28.0% 42.4% -34.3% 31.4%
2000 36.8% -25.0%

Month by Month Performance

Returns Vs Risk

Asset Allocation

Breakdown

30/06/2017

Top 10 Holdings

Stock Size
Regeneron Pharmaceuticals Inc ORD 7.02
Gilead Sciences Inc ORD 6.65
Celgene Corp ORD 6.15
Biogen Inc ORD 5.86
Amgen Inc ORD 5.77
Incyte Corp ORD 5.17
Vertex Pharmaceuticals Inc ORD 3.62
Alexion Pharmaceuticals Inc ORD 3.06
TESARO Inc ORD 2.66
Neurocrine Biosciences Inc ORD 2.52
30/06/2017

Registered For Sale In

  1. Austria
  2. Belgium
  3. Denmark
  4. Finland
  5. France
  6. Germany
  7. Italy
  8. Luxembourg
  9. Netherlands
  10. Singapore
  11. Spain
  12. Sweden
  13. Switzerland
  14. United Kingdom

Fund Info

  • Launch date06/04/2000
  • Share Class size841Mn
  • Base currencyUSD
  • ISIN LU0108459040

Purchase Info

  • Min. initial investment0
  • Min. regular additional investment0

Charges

  • Annual management1.50%
  • Initial investment3.5

Related News

Analyst watch: Candriam boosts biotech team

Healthcare specialist Rudi Van den Eynde set to be assisted in drug development knowledge in biotechnology space.

Biotech star’s team bolstered with new hire

Candriam Investors Group appoints senior analyst to join Citywire A-rated manager's specialist healthcare team.

Biotech equity’s most consistent managers of the past five years

Citywire Global uncovers the pair of sector specialists continually staying ahead of the average peer over the past half-decade.

Part-time players could derail biotech boom, warns healthcare star

Citywire A-rated specialist Rudi Van Den Eynde believes over-exposure from generalist investors could hurt the sector.

Healthcare star: biotech’s M&A boom shows no sign of slowing

Citywire A-rated Rudi Van Den Eynde says although activity is in ‘full swing’ it is time position for more pick-ups.

Bright lights in biotech: two most consistent managers revealed

The specialist health care sector has received increased interest over the past five years but only two managers have regularly beaten the average manager.

Dexia AM strengthens healthcare funds team

Franco-Belgian investment firm appoints biotech specialist as it seeks to broaden knowledge on healthcare fund.

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated).